Table 3 Carriers of the LRRK2 p.G2019S variant across different cohorts

From: Genome-wide association study of REM sleep behavior disorder in Parkinson’s disease

Cohort

Non-carriers PD-RBD, N

Carriers PD-RBD, N (%)

Non-carriers PD + RBD, N

Carriers PD + RBD, N (%)

Oslo

156

1 (0.64%)

122

1 (0.81%)

Lund

552

3 (0.54%)

364

1 (0.27%)

McGill

212

5 (2.30%)

282

3 (1.05%)

AMP-PD

258

9 (3.37%)

110

1 (0.90%)

Sydney

115

1 (0.86%)

98

1 (1.01%)

Tuebingen

365

0 (0.00%)

641

0 (0.00%)

Barcelona

45

0 (0.00%)

100

0 (0.00%)

PRoBaND

1132

2 (0.18%)

582

3 (0.51%)

PFP

328

9 (2.67%)

246

6 (2.38%)

OPDC

537

2 (0.37%)

274

0 (0.00%)

Kosice

216

1 (0.46%)

101

0 (0.00%)

23andMe

8459

248 (2.85%)

2584

19 (0.73%)

Totala

12,010

281 (2.29%)

4863

35 (0.71%)

  1. PD-RBD participants without REM sleep behavior disorder (RBD), PD + RBD participants with RBD, N number of participants, % percentage of participants, Oslo Oslo University Hospital, Lund Lund University, McGill McGill University, AMP-PD Accelerating Medicines Partnership Parkinson’s disease, including the New Discovery of Biomarkers (BioFIND), the Harvard Biomarker Study (HBS) and the Parkinson’s Disease Biomarkers Program (PDBP) cohorts, Sydney University of Sydney, Tuebingen University of Tuebingen, Barcelona Hospital Universitari Mutua de Terrassa, PRoBaND Parkinson’s repository of biosamples and networked datasets, PFP Parkinson’s Families Project, OPDC Oxford Parkinson’s Disease Centre, Kosice Pavol Jozef Šafárik University in Kosice.
  2. aThe total excludes individuals with unknown carrier status for p.G2019S.
Back to article page